AFP1d
Azafaros to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that it will present at J.P. Morgan’s 43rd Annual Healthcare ...
EMA gives OMPD to Actuate’s pancreatic cancer therapy
Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...
Actuate Therapeutics announces EMA granted OMPD to elraglusib
Actuate Therapeutics (ACTU) announced that the European Medicines Agency, EMA, has granted Orphan Medicinal Product Designation, OMPD, to ...
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies ...
Health Kick Podcast: Neurizon gears up for big year in tackling ALS
Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast.